

## **Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)**

**April 27, 2017 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Tuesday, May 30, 2017 at 5:00 p.m. (CET) at the company’s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.**

Shareholders who wish to attend the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on May 23, 2017, and give notice of attendance to the company by e-mail to [annika.lindmark@indexpharma.com](mailto:annika.lindmark@indexpharma.com) or under address: InDex Pharmaceuticals Holding AB, Tomtebodavägen 23a, 171 77 Stockholm, no later than May 23, 2017.

The full notice of the Annual General Meeting (in the Swedish language) is available on the company’s website, [www.indexpharma.com](http://www.indexpharma.com).

### **For more information:**

Peter Zerhouni, CEO

Phone: +46 8 508 847 35

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

### **InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com)

### **Publication**

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 14:30 CET on April 27, 2017.